Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We report the case of a 16-month-old patient with chronic immune thrombocytopenia (ITP) patient who experienced delayed treatment-free response (TFR) after romiplostim treatment. He received intravenous immunoglobulin every month to maintain a platelet count above 20,000/μL for 2 years. Thereafter, he received rituximab and cyclosporine as second-line therapy, with no response, followed by romiplostim. After 4 weeks of treatment, the platelet count was maintained above 50,000/μL. Following 7 months of treatment, he discontinued romiplostim, and the platelet count decreased. His platelet counts remained above 50,000/μL, without any bleeding symptoms, 2 years after romiplostim discontinuation. This is the first report of TFR after romiplostim treatment in pediatric chronic ITP.
Abstract
We report the case of a 16-month-old patient with chronic immune thrombocytopenia (ITP) patient who experienced delayed treatment-free response (TFR) after romiplostim treatment. He received intravenous immunoglobulin every month to maintain a platelet count above 20,000/μL for 2 years. Thereafter, he received rituximab and cyclosporine as second-line therapy, with no response, followed by romiplostim. After 4 weeks of treatment, the platelet count was maintained above 50,000/μL. Following 7 months of treatment, he discontinued romiplostim, and the platelet count decreased. His platelet counts remained above 50,000/μL, without any bleeding symptoms, 2 years after romiplostim discontinuation. This is the first report of TFR after romiplostim treatment in pediatric chronic ITP.
참고문헌 (11)
- 김지윤, "Diagnostic Approach of Childhood Immune Thrombocytopenia", Clinical Pediatric Hematology-Oncology, 25(1), pp.10~16 (2018), 대한소아혈액종양학회[DOI]
- Yeo-Kyeoung Kim, "Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia", Blood Research, 50(1), pp.19~25 (2015), 대한혈액학회
- Neunert CE, "Romiplostim for the management of pediatric immune thrombocytopenia : drug development and current practice", Blood Adv, 3, pp.1907~1915 (2019)
- Tarantino MD, "Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study", Lancet, 388, pp.45~54 (2016)
- Franchini M, "Thrombocytopenia and infections", Expert Rev Hematol, 10, pp.99~106 (2017)
- Thota S, "Immune thrombocytopenia in adults : an update", Cleve Clin J Med, 79, pp.641~650 (2012)
- Kistangari G, "Immune thrombocytopenia", Hematol Oncol Clin North Am, 27, pp.495~520 (2013)
- Kuter DJ, "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial", Lancet, 371, pp.395~403 (2008)
- Mathias SD, "phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents", Pediatr Blood Cancer, 63, pp.1232~1237 (2016)
- Tarantino MD, "Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia", Haematologica, 104, pp.2283~2291 (2019)
- Lozano ML, "Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia", Sci Rep, 9, pp.16680~ (2019)